Clearside Biomedical, Inc. (NASDAQ:CLSD) Q2 2023 Results Conference Call August 14, 2023 4:30 PM ET

Company Participants

Jenny Kobin - IR

George Lasezkay - CEO

Charlie Deignan - CFO

Conference Call Participants

Jon Wolleben - JMP Securities

Shawn Kim - Jones Trading

Rohit Bhasin - Needham & Company

Jack Padavano - Stifel

Yi Chen - H.C. Wainwright

Operator

Greetings, and welcome to the Clearside Biomedical Second Quarter 2023 Financial Results and Corporate Update Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Jenny Kobin of Investor Relations. You may begin.

Jenny Kobin

Good afternoon, everyone, and thank you for joining us on the call today.

Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2022, our quarterly report on Form 10-Q for the quarter ended June 30, 2023, and our other SEC filings available on our website.

In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change. On today's call, we have George Lasezkay, our Chief Executive Officer; and Charlie Deignan, our Chief Financial Officer. After our formal remarks, we will open the call for your questions.

I would now like to turn the call over to George.

George Lasezkay

Thanks, Jenny. The last 6 months have demonstrated that Clearside is the clear leader in delivering agents to the suprachoroidal space. We have a proprietary suprachoroidal space injection technology that utilizes our patented SCS microinjector. We're able to deliver small molecules and gene therapy behind the visual field, targeting multiple retinal diseases.

We have the first and only FDA-approved SCS product with XIPERE, and we have four external validating SCS delivery collaborations as well as an early-stage internal research and development pipeline. Importantly, as we expand our development opportunities, both internally and with our partners, our versatile therapeutic platform continues to grow together with our licensing partners, there are now six ongoing SCS trials in five different indications utilizing four potential therapies.